| STOCK FALLS |
| The News You Need Before You Need It |
Filed under: Competitive strategy , Google (GOOG) , Small business Increasingly, before consumers make a purchase, the first step is the web.
Continued here:
Entrepreneur’s Journal: How to use Google’s AdWords to ramp up new customers
Filed under: Earnings reports , Forecasts , Google (GOOG) , Citigroup Inc. (C) , JPMorgan Chase (JPM) , Bank of America (BAC) , Baxter Intl (BAX) , Goldman Sachs Group (GS) The earnings crunch ramps up this week, and again expectations are generally low. Among the so-called bellwethers that are expected to report lower earnings year over year are CSX Corp
Go here to see the original:
The week in preview: Another tough quarter for the big banks
Filed under: Stocks to Buy Curis (NASDAQ: CRIS ) is a speculative stock — no approved product and no revenue — that, in former markets, would sell for $10 - $12. It is now around a buck and a half, after doubling in the past few months. CRIS focuses on cancer treatments, and is partnered with Genentech/Roche.
View post:
Biotech stock #4: Curis (CRIS)
